Copyright
©The Author(s) 2023.
World J Clin Cases. Apr 16, 2023; 11(11): 2474-2481
Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2474
Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2474
Table 1 European League Against Rheumatism definition of difficult-to-treat rheumatoid arthritis
EULAR definition of D2T RA |
1 Treatment according to the recommendations of the European League against rheumatism, treatment failure ≥ two biological / tsDMARDs (with different mechanism)1 after csDMARD treatment failure (unless there are contraindications)2. |
2 Signs indicating active/progressive diseases are defined as ≥ one of them: |
(1) At least moderate disease activity (based on validated composite indicators, including joint counts, such as DAS28-ESR > 3.2 or CDAI > 10). |
(2) Signs (including acute phase reactants and imaging) and / or symptoms indicating active disease (joint related or other). |
(3) No reduction in glucocorticoid treatment (less than 7.5 mg / day prednisone or equivalent). |
(4) Rapid radiographic progress (with or without signs of active disease)3. |
(5) According to the above criteria, the disease is well controlled, but there are still RA symptoms, resulting in a decline in the quality of life. |
3 Rheumatologists and/or patients believe that there are problems in the management of signs and/or symptoms. |
- Citation: Qi JP, Jiang H, Wu T, Zhang Y, Huang W, Li YX, Wang J, Zhang J, Ying ZH. Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report. World J Clin Cases 2023; 11(11): 2474-2481
- URL: https://www.wjgnet.com/2307-8960/full/v11/i11/2474.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i11.2474